Access to anti-retroviral drugs, male in Kazakhstan

Kazakhstan: Access to anti-retroviral drugs, male was 88.0% in 2024. ◆ Volatile

Latest (2024)
88.0%
Change on year
up 6.0%
World rank
23rd
of 141 countries
All-time high
88.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Kazakhstan, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 3 %2006: 4 %2007: 4 %2008: 4 %2009: 6 %2010: 8 %2011: 11 %2012: 15 %2013: 18 %2014: 21 %2015: 26 %2016: 30 %2017: 40 %2018: 51 %2019: 57 %2020: 64 %2021: 69 %2022: 76 %2023: 83 %2024: 88 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Kazakhstan is 88.0%, measured in 2024. That is the highest value across all 25 years on record.

That represents a change of up 6.0% on the previous year and up 319.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Kazakhstan peaked at 88.0% in 2024 and was at its lowest, 0.0%, in 2000.

Kazakhstan ranks 23rd of 141 countries on this measure, in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Kazakhstan, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Kazakhstan, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 3.0%
2006 4.0% +33.3%
2007 4.0% +0.0%
2008 4.0% +0.0%
2009 6.0% +50.0%
2010 8.0% +33.3%
2011 11.0% +37.5%
2012 15.0% +36.4%
2013 18.0% +20.0%
2014 21.0% +16.7%
2015 26.0% +23.8%
2016 30.0% +15.4%
2017 40.0% +33.3%
2018 51.0% +27.5%
2019 57.0% +11.8%
2020 64.0% +12.3%
2021 69.0% +7.8%
2022 76.0% +10.1%
2023 83.0% +9.2%
2024 88.0% +6.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.1% 0.0% 6.0% 10
2010s 27.7% 8.0% 57.0% 10
2020s 76.0% 64.0% 88.0% 5

Countries ranked near Kazakhstan

  1. 23 Australia 88.0% compare
  2. 23 Belgium 88.0% compare
  3. 23 Lesotho 88.0% compare

See the full ranking of 160 places →

More gender data for Kazakhstan

All data for Kazakhstan →

Frequently asked questions

What is access to anti-retroviral drugs, male in Kazakhstan?
Access to anti-retroviral drugs, male in Kazakhstan was 88.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Kazakhstan?
The highest recorded value was 88.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Kazakhstan?
The lowest recorded value was 0.0% in 2000.
How does Kazakhstan rank for access to anti-retroviral drugs, male?
Kazakhstan ranks 23rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Kazakhstan?
Over the last ten years it is up 319.0%. The long-run trend across the full record is volatile.
Where does this Kazakhstan data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Kazakhstan. Statizoid, drawing on UNAIDS estimates. Retrieved 12 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/kazakhstan/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/kazakhstan/">Access to anti-retroviral drugs, male in Kazakhstan</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.